Aggregated price index with volume information
Summary:
- Alzheimer Treatment stocks down 0.3% on average while median return down 0.3% in a day
- Alzheimer Treatment stocks down 7.6% on average while median return down 11.0% in a week
- Alzheimer Treatment stocks down 11.4% on average while median return down 13.2% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $MRK 1.6%
- 1M losers are : Losers for past month are $WVE -21.2%, $DNLI -24.8%, $AVXL -26.2%, $VYGR -27.5%, $ACIU -27.5%
- 1W winners are : Winners for past week are $ABBV 2.5%, $AMGN 0.6%
- 1W losers are : Losers for past week are $ATHA -12.7%, $ANVS -13.5%, $SAVA -13.7%, $ACIU -13.9%, $WVE -16.0%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 20.4%, for the past 3 months is 16.5%
In the past month for a 5 days rolling window, the highest corrrelation is 42.5%, the lowest correlation is 1.8%, the latest correlation is 1.8%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 73.9% between AVXL and DNLI
The lowest correlation is -46.1% between CYTH and IONS
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
SAN DIEGO, April 19, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units ("RSUs") to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic
In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karu...